ArticleCardio-oncology (London, England)2026
Cardiac magnetic resonance with myocardial strain as a predictor of anthracycline-induced cardiotoxicity in patients with lymphoma: a prospective multimodality study.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundCancer therapy-related cardiac dysfunction (CTRCD) is a frequent and clinically relevant complication in patients with lymphoma treated with anthracyclines. Early identification of subclinical myocardial injury is critical to prevent progression to overt heart failure and to avoid chemotherapy dose reductions that may compromise oncologic outcomes. We aimed to evaluate the role of cardiac magnetic resonance (CMR) with T1 mapping and feature-tracking myocardial strain, in comparison with transthoracic echocardiography (TTE) and circulating biomarkers, for the early detection of CTRCD in lymphoma patients receiving anthracycline-based chemotherapy.
methodsIn this prospective, single-center observational study, forty-nine adult patients with lymphoma scheduled for anthracycline-based chemotherapy underwent serial assessment of high-sensitivity cardiac troponin T (hs-cTnT), NT-proBNP, TTE, and CMR at baseline (visit 0), after the third chemotherapy cycle (visit 1), and at chemotherapy completion (visit 2). TTE was repeated at 12-month follow-up (visit 3). CMR included cine imaging, T1 mapping with extracellular volume (ECV) quantification, late gadolinium enhancement, and feature-tracking strain analysis (global longitudinal [GLS], circumferential [GCS], and radial [GRS] strain). CTRCD was defined and graded according to the 2022 ESC Cardio-Oncology Guidelines.
resultsThe median age of patients was 46 (29.5-62) years; 53.1% were female. The mean cumulative doxorubicin dose was 295 ± 57 mg/m². hs-cTnT levels increased progressively from baseline (0.006 ± 0.005 ng/mL) to visit 2 (0.022 ± 0.016 ng/mL; p < 0.001), while NT-proBNP did not change significantly (p = 0.086). TTE showed a significant decline in LVEF by the Simpson method (62.92 ± 5.61% to 60.23 ± 5.41%; p = 0.037) and progressive worsening of GLS (- 19.84 ± 2.35% to - 18.31 ± 2.73%; p = 0.001). CMR-derived LVEF also declined (61.98 ± 6.08% to 57.34 ± 7.29%; p < 0.001), accompanied by significant deterioration of GLS, GCS, and GRS (p < 0.001 for all). CTRCD was identified in 7 patients (14.9%) by CMR and 5 (10.6%) by TTE (p = 0.625), with substantial agreement between modalities (κ = 0.619; p < 0.001). A relative GLS decline > 15% was observed by CMR in 34.1% of patients at visit 1 and 43.9% at visit 2, exceeding the corresponding TTE-detected rates (15.2% and 18.6%).
conclusionsCMR-derived strain identified myocardial functional abnormalities during anthracycline therapy. Whether these abnormalities represent earlier manifestations of clinically relevant cardiotoxicity requires confirmation in larger prospective studies with longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.